American Society of Hirudotherapy

Revisiting Heparin-Induced Thrombocytopenia among Patients Undergoing Free Tissue Transfer: A Systematic Review

Systematic review published in Journal of reconstructive microsurgery (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureDrug DevelopmentYamin et al. · Journal of reconstructive microsurgery, 2026

Abstract

Heparin is frequently used to mitigate the risk of thrombosis in microsurgical free tissue transfer. Although rare, heparin-induced thrombocytopenia (HIT) is a severe, life-threatening complication that can arise in patients exposed to heparin products. This systematic review aims to examine patterns in demographics, flap characteristics, diagnostic approaches, and treatment protocols for HIT following free flap reconstruction.A systematic search was conducted across PubMed, MEDLINE, and Web of Science, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Search terms included "heparin-induced thrombocytopenia," "HIT syndrome," "free flaps," "microsurgery," "plastic surgery," and "reconstructive surgery." Case reports or series written in English that presented patients developing HIT following free flap procedures were included. Eligibility criteria are accessible on the International Prospective Register of Systematic Reviews (PROSPERO; CRD42025650125).A total of 15 articles were included, encompassing a total of 23 free flap reconstruction cases. The median patient age was 52 years, with male predominance (69.6). Lower extremity reconstruction was most common (47.8%), primarily using anterolateral thigh flaps (39.1%). Median 4T score was 6, median time to HIT diagnosis was 6 days, and median nadir platelet count was 72 × 103/μL. Thrombotic complications were common, with venous thrombosis (34.8%) predominating. Argatroban (26.1%) was the most frequently used alternative anticoagulant, while warfarin (30.4%) was the most common discharge medication. Overall flap survival was 43.5%. Meta-analysis revealed no significant difference in flap survival between anticoagulation strategies (95% CI: 0.38-2.63, p = 1.000).HIT represents a rare but devastating complication in free flap reconstruction, with approximately half of the affected flaps failing despite intervention. Although no single anticoagulation strategy demonstrated superior outcomes, expeditious diagnosis and treatment may improve flap salvage rates. This review provides a foundation for developing standardized protocols for HIT management in microsurgical patients.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansHeparinThrombocytopeniaFree Tissue FlapsAnticoagulantsPostoperative ComplicationsPlastic Surgery ProceduresMicrosurgeryThrombosis

Summary

A systematic review of 23 reported cases of heparin-induced thrombocytopenia after free flap reconstruction found venous thrombosis the predominant complication, overall flap survival of 43.5%, and no anticoagulation strategy clearly superior for flap outcome.

Context

This systematic review examined heparin-induced thrombocytopenia (HIT) following microsurgical free tissue transfer, identifying 23 cases across 15 articles with a median 4T score of 6, median time to diagnosis of 6 days, and an overall flap survival rate of only 43.5%. Argatroban (26.1%) was the most frequently used alternative anticoagulant, while meta-analysis revealed no significant difference in flap survival between anticoagulation strategies. Leech therapy may be employed for flap salvage in reconstructive microsurgery, though this abstract does not mention leeches, hirudin, or bivalirudin. This review focuses on HIT management specifically and does not involve leech therapy or leech-derived compounds; the small number of cases limits generalizability.

Citation

Reference (Vancouver style)

Yamin M, Tobin M, Raquepo T, Park JB, Lee D, Escobar-Domingo MJ, et al. Revisiting Heparin-Induced Thrombocytopenia among Patients Undergoing Free Tissue Transfer: A Systematic Review. J Reconstr Microsurg. 2026;42(6):473-481. doi:10.1055/a-2687-0443. PMID: 40840544

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.